U.S. Pharmaceutical Distributor Executive Acquires $1.4 Billion in Company Stock

On May 28, D. Mark Durcan, a director of Cencora, Inc. (NYSE: COR), purchased 4,000 shares of the company’s common stock in an open-market transaction at an average price of $266.26 per share, investing approximately $1.07 million.

Following this transaction, Durcan’s direct holdings rose to just over 27,000 shares, valued at roughly $7.4 to $7.5 million based on prevailing market prices.

Separately, on May 27 Cencora named Eva C. Boratto as its new chief financial officer and reaffirmed its fiscal 2026 adjusted diluted EPS guidance of $17.70 to $17.90 per share, maintaining its prior outlook.

Earlier in March, the company continued to bolster its specialty-therapy portfolio by agreeing to acquire the retina business of EyeSouth Partners for approximately $1.1 billion.

Headquartered in Conshohocken, Pennsylvania, Cencora, Inc. is a global pharmaceutical wholesaler and distributor. Formerly known as AmerisourceBergen until its rebranding to Cencora in 2023, the company is listed on the New York Stock Exchange and is a member of the S&P 500. With annual revenues exceeding $300 billion, Cencora supplies pharmaceuticals and healthcare products to hospitals, pharmacies and clinics worldwide, offering comprehensive solutions across human and animal health.